Distinguished in Fibrosarcoma

Dr. Eric S. Nadler

Oncology
Baylor Scott & White Health
Texas Oncology, P.A.
3410 Worth Street, Suite 400, 
Dallas, TX 
Offers Telehealth
26 Years of Experience
Distinguished in Fibrosarcoma
Baylor Scott & White Health
Texas Oncology, P.A.
3410 Worth Street, Suite 400, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eric Nadler is an Oncologist in Dallas, Texas. Dr. Nadler has been practicing medicine for over 26 years and is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Lung Cancer, Adenoid Cystic Carcinoma, Bone Tumor, and Pleuropulmonary Blastoma.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Fibrosarcoma.

Graduate Institution
Harvard Medical School, 2000.0
Residency
Internal Medicine, Brigham & Womens Hospital
Specialties
Oncology
Licenses
Internal Medicine in TX
Fellowships
Medical Oncology, Dana Farber Cancer Institute
Medical Oncology, Dana Farber Cancer Institute Yawkey
Hospital Affiliations
Baylor University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Texas Oncology, P.A.
3410 Worth Street, Suite 400, Dallas, TX 75246
Call: 972-449-0540

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection
A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Combination product
Study Drugs: Pembrolizumab, PDS0101
Study Phase: Phase 2
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Topotecan
Study Phase: Phase 1/Phase 2
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Drug, Biological
Study Drugs: Autologous Epstein Barr Virus-Specific Cytotoxic T Cells, Gemcitabine, Carboplatin
Study Phase: Phase 3
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
Enrollment Status: Terminated
Publish Date: January 03, 2022
Intervention Type: Drug
Study Phase: Phase 2
The Optimal Tube Feeding Method in Head and Neck Cancer Patients: A Comparison Between Bolus, Gravity, and Tube Feeding Pump.
The Optimal Tube Feeding Method in Head and Neck Cancer Patients: A Comparison Between Bolus, Gravity, and Tube Feeding Pump.
Enrollment Status: Terminated
Publish Date: May 22, 2019
Intervention Type: Procedure, Device
Study Phase: Not Applicable
View 6 Less Clinical Trials

26 Total Publications

Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.
Journal: Therapeutic advances in medical oncology
Published: May 01, 2025
View All 26 Publications
Similar Doctors
Advanced in Fibrosarcoma
Dr. Robert G. Mennel
Internal Medicine | Oncology
Advanced in Fibrosarcoma
Dr. Robert G. Mennel
Internal Medicine | Oncology

Texas Oncology, P.A.

3410 Worth Street, Suite 400, 
Dallas, TX 
 (0.1 miles away)
972-449-0540
Experience:
56+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Mennel is an Internal Medicine specialist and an Oncologist in Dallas, Texas. Dr. Mennel has been practicing medicine for over 56 years and is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Angiosarcoma, Adult Soft Tissue Sarcoma, Angiosarcoma of the Scalp, and Mesenchymoma.

Advanced in Fibrosarcoma
Dr. Sanjay Chandrasekaran
Hematology | Oncology
Advanced in Fibrosarcoma
Dr. Sanjay Chandrasekaran
Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (4.3 miles away)
214-645-0624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sanjay Chandrasekaran is a Hematologist and an Oncologist in Dallas, Texas. Dr. Chandrasekaran is rated as an Advanced provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Bone Tumor, Liposarcoma, Epithelioid Sarcoma, and Myxoid Liposarcoma.

Advanced in Fibrosarcoma
Dr. Daniel Y. Wang
Hematology Oncology | Oncology | Hematology
Advanced in Fibrosarcoma
Dr. Daniel Y. Wang
Hematology Oncology | Oncology | Hematology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (4.3 miles away)
214-648-0624
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Wang is a Hematologist Oncology specialist and an Oncologist in Dallas, Texas. Dr. Wang is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Mesothelioma, Melanoma, Bone Tumor, and Liposarcoma. Dr. Wang is currently accepting new patients.

VIEW MORE FIBROSARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nadler's expertise for a condition
ConditionClose
    • Distinguished
    • Adenoid Cystic Carcinoma
      Dr. Nadler is
      Distinguished
      . Learn about Adenoid Cystic Carcinoma.
      See more Adenoid Cystic Carcinoma experts
    • Adult Soft Tissue Sarcoma
      Dr. Nadler is
      Distinguished
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Bone Tumor
      Dr. Nadler is
      Distinguished
      . Learn about Bone Tumor.
      See more Bone Tumor experts
    • Epithelioid Sarcoma
      Dr. Nadler is
      Distinguished
      . Learn about Epithelioid Sarcoma.
      See more Epithelioid Sarcoma experts
    • Fibrosarcoma
      Dr. Nadler is
      Distinguished
      . Learn about Fibrosarcoma.
      See more Fibrosarcoma experts
    • Liposarcoma
      Dr. Nadler is
      Distinguished
      . Learn about Liposarcoma.
      See more Liposarcoma experts
    View All 14 Distinguished Conditions
    • Advanced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Nadler is
      Advanced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Nadler is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Alveolar Soft Part Sarcoma
      Dr. Nadler is
      Advanced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Angiosarcoma
      Dr. Nadler is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Angiosarcoma of the Scalp
      Dr. Nadler is
      Advanced
      . Learn about Angiosarcoma of the Scalp.
      See more Angiosarcoma of the Scalp experts
    • EGFR Positive Lung Cancer
      Dr. Nadler is
      Advanced
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    View All 25 Advanced Conditions
    • Experienced
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Nadler is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Nadler is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Nadler is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Agranulocytosis
      Dr. Nadler is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Anal Cancer
      Dr. Nadler is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Anaplastic Thyroid Cancer
      Dr. Nadler is
      Experienced
      . Learn about Anaplastic Thyroid Cancer.
      See more Anaplastic Thyroid Cancer experts
    View All 54 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment